Karyopharm Therapeutics Reports Q1 2025 Earnings and Clinical Progress

Karyopharm Therapeutics INC ( (KPTI) ) has released its Q1 earnings. Here is a breakdown of the information Karyopharm Therapeutics INC presented to its investors.

Karyopharm Therapeutics Inc. is a commercial-stage pharmaceutical company focused on developing novel cancer therapies, particularly in the field of nuclear export dysregulation, with its lead product XPOVIO (selinexor) approved for multiple oncology indications. In its first quarter of 2025, Karyopharm reported total revenue of $30 million, a slight decrease from the previous year, primarily due to increased product return reserves. Despite this, demand for XPOVIO increased by 5%, and the company saw a significant rise in royalty revenue from international partners. The company is advancing its clinical trials, notably the Phase 3 SENTRY trial for myelofibrosis, which passed a futility analysis and is nearing full enrollment. Karyopharm also reported a net loss of $23.5 million, an improvement from the previous year’s loss, and is exploring options to extend its cash runway. Looking ahead, Karyopharm remains focused on advancing its clinical programs and maintaining its revenue guidance for 2025, with expectations to fund operations into early 2026.